Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of M6620 (VX-970, Berzosertib) in Combination With Cisplatin and XRT in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)

NCT02567422 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02567422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02567422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of M6620 (VX-970, Berzosertib) in Combination With Cisplatin and XRT in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 17, 2017
Completion date
May 14, 2027
Enrollment
43 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck carcinoma of unknown primary, head and neck squamous cell carcinoma, stage iii hypopharyngeal squamous cell carcinoma ajcc v7, stage iii laryngeal squamous cell carcinoma ajcc v6 and v7, stage iii oral cavity squamous cell carcinoma ajcc v6 and v7, stage iii oropharyngeal squamous cell carcinoma ajcc v7, stage iii sinonasal squamous cell carcinoma ajcc v6 and v7, stage iv hypopharyngeal squamous cell carcinoma ajcc v7, stage iv laryngeal squamous cell carcinoma ajcc v7, stage iv oral cavity squamous cell carcinoma ajcc v6 and v7, stage iv oropharyngeal squamous cell carcinoma ajcc v7, stage iv sinonasal squamous cell carcinoma ajcc v7